Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | IL2 | P60568 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL471858 | 0.86 | KDM4E (0.60) | KDM4EHRH3CYP2D6LMNAMAPT | |
| SCHEMBL1621903 | 0.81 | KDM4E (0.50) | KDM4EHRH3CYP2D6LMNAMAPT | |
| SCHEMBL2088974 | 0.81 | KDM4E (0.51) | KDM4EHRH3CYP2D6LMNAMAPT | |
| SCHEMBL20409590 | 0.79 | KDM4E (0.53) | KDM4EHRH3CYP2D6LMNAMAPT | |
| SCHEMBL3942245 | 0.79 | KDM4E (0.53) | KDM4EHRH3CYP2D6LMNAMAPT | |
| SCHEMBL17841463 | 0.78 | KDM4E (0.50) | KDM4EHRH3CYP2D6LMNAMAPT | |
| SCHEMBL2557980 | 0.78 | HRH3 (0.40) | KDM4EHRH3CYP2D6LMNAMAPT | |
| SCHEMBL3762622 | 0.77 | KDM4E (0.51) | KDM4EHRH3CYP2D6LMNAMAPT | |
| SCHEMBL20411007 | 0.77 | HRH3 (0.54) | KDM4EHRH3CYP2D6LMNAMAPT | |
| SCHEMBL4447566 | 0.77 | KDM4E (0.51) | KDM4EHRH3CYP2D6LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | KDM4E 2952/4885HRH3 235/4885CYP2D6 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.